14-3-7　ⓔ文献

  1. Yokoyama H, Taguchi T, et al: Committee for the Standardization of Renal Pathological D, for Renal B, and Disease Registry in the Japanese Society of N. Membranous nephropathy in Japan: analysis of the Japan Renal Biopsy Registry (J–RBR). Clin Exp Nephrol, 2012; 16: 557–563.

  2. Sugiyama H, Yokoyama H, et al: Japan Renal Biopsy Registry and Japan Kidney Disease Registry: Committee Report for 2009 and 2010. Clin Exp Nephrol, 2013; 17: 155–173.

  3. Beck LH Jr, Bonegio RG, et al: M–type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med, 2009; 361: 11–21.

  4. Akiyama S, Akiyama M, et al: Prevalence of anti–phospholipase A2 receptor antibodies in Japanese patients with membranous nephropathy. Clin Exp Nephrol, 2015; 19: 653–660.

  5. Hoxha E, Thiele I, et al: Phospholipase A2 receptor autoantibodies and clinical outcome in patients with primary membranous nephropathy. J Am Soc Nephrol, 2014; 25: 1357–1366.

  6. Tomas NM, Beck LH Jr, et al: Thrombospondin type–1 domain–containing 7A in idiopathic membranous nephropathy. N Engl J Med, 2014; 371: 2277–2287.

  7. Tomas NM, Meyer–Schwesinger C, et al: A Heterologous Model of Thrombospondin Type 1 Domain–Containing 7A–Associated Membranous Nephropathy. J Am Soc Nephrol, 2017; 28: 3262–3277.

  8. Sethi S, Debiec H, et al: Neural epidermal growth factor–like 1 protein (NELL–1) associated membranous nephropathy. Kidney Int, 2020; 97: 163–174.

  9. Hoshino J, Ubara Y, et al: Outcome and treatment of bucillamine–induced nephropathy. Nephron Clin Pract, 2006; 104: c15–19.

  10. von Haxthausen F, Reinhard L, et al: Antigen–Specific IgG Subclasses in Primary and Malignancy–Associated Membranous Nephropathy. Front Immunol, 2018; 9: 3035.

  11. Hoxha E, Wiech T, et al: A Mechanism for Cancer–Associated Membranous Nephropathy. N Engl J Med, 2016; 374: 1995–1996.

  12. Hunley TE, Corzo D, et al: Nephrotic syndrome complicating α–glucosidase replacement therapy for Pompe disease. Pediatrics, 2004; 114: e532–e535.

  13. Debiec H, Valayannopoulos V, et al: Allo–immune membranous nephropathy and recombinant aryl sulfatase replacement therapy: a need for tolerance induction therapy. J Am Soc Nephrol, 2014; 25: 675–680.

  14. Fujimoto S, Hara S, et al: Nephrotic syndrome caused by membranous nephropathy: response to a short course of cyclophosphamide alternating with prednisolone. Intern Med, 2004; 43: 30–34.

  15. Barbour SJ, Greenwald A, et al: Disease–specific risk of venous thromboembolic events is increased in idiopathic glomerulonephritis. Kidney Int, 2012; 81: 190–195.

  16. 厚生労働省難治性疾患克服事業進行性腎障害に関する調査研究班：エビデンスに基づくネフローゼ症候群診療ガイドライン2017，東京医学社，2017．

  17. Shiiki H, Saito T, et al: Prognosis and risk factors for idiopathic membranous nephropathy with nephrotic syndrome in Japan. Kidney Int, 2004; 65: 1400–1407.

  18. KDIGO Clinical Practice Guideline for Glomerulonephritis. Kidney Int Suppl, 2012; 2: 1–138.

  19. Yamamoto R, Imai E, et al: Regional variations in immunosuppressive therapy in patients with primary nephrotic syndrome: the Japan nephrotic syndrome cohort study. Clin Exp Nephrol, 2018; 22: 1266–1280.